Novartis to help Roche make potential COVID drug

Donnerstag, 15. April 2021 08:53

Novartis said on Thursday it signed an agreement with Roche to help it make Actemra/RoActemra (tocilizumab), a drug for rheumatoid arthritis which is also being tested as a potential treatment for COVID-19 associated pneumonia.

Novartis is set to manufacture the active pharmaceutical ingredient (API) for Actemra/RoActemra at its Singapore factory. Under the initial agreement, technology and expertise will be transferred to the Novartis site.

The Swiss pharmaceutical company already signed agreements with CureVac and Pfizer to help them boost COVID-19 vaccine production.

Enlaces afines: Roche HoldingNovartis AG
Autor:
Breaking the News / NP